The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...
ImmunityBio stock rises after 85% response rate in bladder cancer study, topping BCG alone; FDA filing planned for 2026.
WASHINGTON (DC News Now) — September is Prostate Cancer Awareness Month, and according to the National Cancer Institute (NCI), approximately one in eight men will be diagnosed with prostate cancer in ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) ...
104.5 WOKV on MSN
Local hospital gets new technology to perform non-invasive procedure to remove liver cancer
A local hospital is using new technology to remove liver cancer without invasive surgery.
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has ...
SAN FRANCISCO, May 22, 2025 /PRNewswire/ -- OncoSwab, a biotechnology company focused on early detection of cancer through non-invasive molecular testing, today announced it has entered into a ...
STATEN ISLAND, N.Y. — Northwell Staten Island University Hospital (SIUH) has announced the addition of a new, non-invasive treatment for localized prostate cancer, which provides precision in ...
ImmunityBio Inc. IBRX shares are up on Monday following the company’s announcement of significant revenue growth. • ...
See how Specialists in Dermatology in The Woodlands and Houston achieves a 99% skin cancer cure rate with Mohs surgery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results